Priothera receives a European Union grant of nearly €685.000 for the development of its innovative treatment for hematologic cancers
As part of the 2021–2027 FEDER-FTJ-FSE+ Program for the Grand Est and Vosges Massif region
St-Louis, France – July 11, 2025 – Priothera, a late-stage biopharmaceutical company specializing in the development of innovative oncology treatments, today announces that it has secured funding of €684,939 from the Fondss pour une Transition Juste (FTJ) – Just Transition Fund – under the 2021–2027 FEDER-FTJ-FSE+ Program for the Grand Est and Vosges Massif region, managed by the Grand Est Regional Council.
This grant will support the rollout of the pivotal Phase 3 MOTRANS clinical trial, conducted by Priothera for the development of its drug candidate, an oral modulator of sphingosine-1-phosphate (S1P) receptors. Mocravimod aims to significantly improve care for patients with acute myeloid leukemia (AML) and other hematologic cancers when used in association with allogenic hematopoietic stem cell transplantation (allo-HCT).
The European funding will strengthen the implementation of the clinical study in specialized hemato-oncology centers in the Grand Est region – a strategic area for medical research and innovation in cell therapy.
Florent Gros, CEO and co-founder of Priothera, stated: “We are extremely grateful for the European Union’s support, which demonstrates its confidence in us. This funding validates the relevance of our approach and our commitment to developing mocravimod, an innovative treatment for patients with acute myeloid leukemia. This support reinforces our ambition to offer an effective and sustainable therapy, while also actively contributing to regional economic dynamism and the development of globally competitive technological expertise.”
The results of the MOTRANS project could position mocravimod as a new standard of care in the treatment of hematologic cancers and establish Priothera as a key player in oncology, with significant impacts on public health, the company’s competitiveness, and local economic growth.
.
About the Fonds pour une Transition Juste (FTJ) – Just Transition Fund – The FTJ is a European fund designed to support French regions affected by the ecological transition. In the Grand Est region, it finances projects that promote employment, training, and the development of sustainable activities in industrial areas undergoing transformation.
About mocravimod
This novel treatment approach – mocravimod being the only S1P receptor modulator in development to treat blood cancers – tackles a high unmet medical need and aims to improve treatment outcomes and patients’ quality of life.
About Priothera
Priothera is a late-stage biopharma company pioneering the development of mocravimod, a potential new standard of care in hematologic cancers, in combination with cellular therapies such as hematopoietic cell transplantation and CAR-T cell therapies. Mocravimod is being developed as an adjunctive and maintenance therapy for hematological malignancies, focusing initially on acute myeloid leukemia (AML), in combination with allogeneic hematopoietic cell transplant (allo-HCT). Mocravimod is currently the only treatment with the potential to reduce transplant side effects of graft-versus-host disease (GvHD) without compromising the graft’s anticancer effect against leukemia (Graft-versus-Leukemia, or GvL), thereby enhancing the curative potential of allo-HCT.
Founded in 2020, Priothera operates in France, with headquarters in Dublin. The company is led by a highly experienced management team with deep expertise in hematology, oncology, immunology and cell-based therapies. Priothera is backed by leading international life sciences investors, including Fountain Healthcare Partners, abrdn, EarlyBird Venture Capital, BEI and Bpifrance Grand Est.